CLINICAL STUDIES
ONGOING CLINICAL STUDIES – CANINE AND FELINE SPECIES
Innovative immunotherapy for solid tumors (recruitment in progress)
16-ONCO-07
Innovative immunotherapy for solid tumors
Objectives
To evaluate the efficacy and safety of a new immunotherapy for the treatment of solid tumors accessible to injections
Indications
Solid tumor of the head and neck, skin tumor, melanoma, breast carcinoma, soft tissue sarcoma
Primary criteria
To evaluate tumor response and treatment safety after combined intratumoral and intravenous injection
Study duration
7 weeks including :
– 1 inclusion visit ;
– 2 treatments cycles with hospitalization
– 2 follow-up visits
– Surgical resection of the tumor
Assessment
Clinical and biological examination (blood and urine samples), CT scan, tumor analysis after surgery
Oral treatment for cerebral gliomas (recruitment in progress)
22-BIV-01
Oral treatment for cerebral gliomas (recruitment in progress)
Objective
To evaluate the efficacy and safety of an innovative oral treatment for high-grade gliomas
Primary criteria
To evaluate tumor response and safety of oral therapy
Study duration
Active phase : 6 weeks of treatment with MRI follow-up
Follow-up phase : follow-up MRI 6 weeks after treatment discontinuation
Assessment
– Clinical, neurological, biological (blood samples) and MRI examination
– Clinical costs covered by the study
– Extensive preclinical and clinical safety package including pet dogs with high-grade glioma
– Close monitoring of tumor progression
Innovative monoclonal antibody treatment for canine tumors (recruitment in progress)
22-ORK-03
Innovative monoclonal antibody treatment for canine tumors (recruitment in progress)
Objective
To evaluate the efficacy and safety of monoclonal antibody therapy in companion dogs with metastatic, recurrent or resistant cancer
Study description
Compassionate protocol for dogs with metastatic, recurrent or resistant cancer
Indications
Mast cell tumor, breast tumor including inflammatory breast carcinoma, soft tissue sarcoma, melanoma, osteosarcoma, hemangiosarcoma, cutaneous lymphoma (mycosis fungoides), transitional cell carcinoma, myeloma, squamous cell carcinoma or any other carcinoma
Primary criteria
To assess the objective tumor response and safety of intravenous monoclonal antibody infusion
Study duration
10-12 weeks comprising 8 visits including 3 study product infusions and 4 control visits
Assessment
Clinical examination, blood and urine analysis, tumor imaging
Osteoarthritis of the elbow or stifle (recruitment in progress)
20-THV-07
Osteoarthritis of the elbow or stifle (recruitment in progress)
Objective
To confirm the efficacy and safety of a single intra-articular administration of the investigational product in the treatment of osteoarthritis of the elbow or stifle in dogs
Primary criteria
To evaluate the efficacy of the investigational product in reducing the severity of osteoarthritis symptoms, including pain reduction and improved mobility
Study duration
1 screening visit + 1 visit for intra-articular injection of investigational product or treatment simulation + 1 follow-up visit per month for 3 months
Assessment
Clinical (clinical examination, questionnaires to be completed by owner and veterinarian)
Medical device for circulating tumor cells capture (recruitment in progress)
23-SMC-01
Medical device for circulating tumor cells capture (recruitment in progress)
Objective
To assess the safety and efficacy of a medical device for circulating tumor cells (CTCs) capture
Study description
In vitro compliance study of a medical device for circulating tumor cells (CTC) capture in blood samples (18mL) from dogs of carcinoma owners
Primary criteria
Check that cancerous canine blood is not altered during micro-filtration by the CTC capture device, by assessing hemolysis.
Inclusion criteria
Adult dog weighing at least 15 kg, fully grown, vaccination up to date, malignant carcinoma with confirmed metastases or at high risk of metastases (histopathology, cytology available).
Study duration
1 hour per animal
Assessment
Clinical examination, blood sampling for inclusion (CBC and blood smear), study blood sample (18 mL)
Oral treatment for alveolar bone loss (recruitment in progress)
21-VBX-02 :
Oral treatment for alveolar bone loss (recruitment in progress)
Objective
To evaluate the efficacy and tolerability of an innovative oral treatment for the reduction of alveolar bone loss in periodontal disease
Primary criteria
Assessment of blood marker, alveolar bone loss by CT scan and periodontal disease parameters
Study duration
60 to 90 days depending on treatment duration
Assessment
Clinical examination; biological (blood samples); CT scan; assessment of periodontal parameters
Food supplement for pre-diabetic cats (recruitment in progress)
22-ING-01 :
Food supplement for pre-diabetic cats (recruitment in progress)
Objective
To evaluate the long-term safety and efficacy of a dietary supplement on blood glucose homeostasis in cats with spontaneously developing pre-diabetes
Study description
Food supplement for cats with pre-diabetes
Primary criteria
To evaluate the effectiveness of the dietary supplement on blood glucose homeostasis by assessing changes in blood parameter values
Study duration
2 months study per cat, with 3 visits
Assessment
Clinical examination; Blood and urine sampling; Follow-up with owner book
Post-sterilization weight maintenance (recruitment completed)
22-RCA-02
Post-sterilization weight maintenance (recruitment completed)
Objective
To evaluate the efficacy of a weight maintenance diet and its acceptance in neutered dogs
Primary criteria
To evaluate the effectiveness of 4 dry food recipes for weight maintenance in dogs after sterilization, and assess small dog owners’ perceptions of 2 wet foods
To evaluate owner and dog satisfaction with dry and wet foods
Study duration
2 months to 2 months and 2 weeks, depending on inclusion group
Assessment
Clinical (clinical examination, weight measurement and questionnaires)
Oral treatment for osteoarthritis in dogs (recruitment in progress)
22-VBX-01 :
Oral treatment for osteoarthritis in dogs (recruitment in progress)
Objective
Aims to evaluate the efficacy and tolerability of a new treatment for osteoarthritis in dogs
Study description
Aims to evaluate the efficacy and safety of a new treatment for osteoarthritis in dogs. This anti-inflammatory treatment is an A3 adenosine receptor inhibitor, and has an excellent safety profile based on preclinical and clinical results in humans. It is designed to meet the veterinary market’s need for safe, effective anti-inflammatory treatments with few side effects.
Primary criteria
To evaluate the efficacy of an innovative treatment to reduce the severity of osteoarthritis symptoms, assessed on the dog’s mobility using an owner questionnaire
Study duration
3 months
Assessment
Clinical examination, blood test, veterinary and owner questionnaires, activity monitor
Atopic dermatitis (recuitment in progress)
S21068-00
Atopic dermatitis (recuitment in progress)
Objective
To evaluate the efficacy and safety of a new treatment for atopic dermatitis
Primary criteria
To evaluate the efficacy of the treatment in reducing the symptoms of atopic dermatitis, as well as its tolerability
Study duration
1 month for one group of dogs with a visit every two weeks
4 months for the other group, with a visit every two weeks for one month, then one visit per month
Assessment
Clinical (clinical examination, questionnaires), biological (blood and urine samples)
CONTACTS
OCR – Bâtiment IRCL2 Place de Verdun – CS30038 -59041 LILLE Cedex
+33 (0)6 63 51 39 71 – mdubruque@oncovet-clinical-research.com – www.oncovet-clinical-research.com
YOU ARE A VET?
WHY OFFER YOUR CLIENTS TO
PARTICIPATE IN A CLINICAL STUDY?
Participating in clinical trials represents an opportunity of scientific publications for veterinary scientific community
in the field of comparative pathology, an international growing sector.
You give access to your clients to an innovative treatment which is not yet available on the market
You give free access to care for your clients
You offer a therapeutic alternative in case of failure of standard treatments
You take part in the research development in human and veterinary health
You offer a solution for cases without therapeutic options (unresectable malignant tumors)
